Resource Center
Dr. Chemaly and his team at MD Anderson are conducting an ongoing study using CMV T Cell Immunity testing to identify high-risk cellular therapy recipients for clinically significant CMV infection, regardless of letermovir prophylaxis. They are evaluating early treatment benefits for low-level CMV viremia in patients not on letermovir prophylaxis and assessing the test's utility in managing CMV viremia across high and low-risk patient groups. Includes a Q&A Session.
This bi-lateral lung transplant recipient is a 65 year-old male patient who received his lung transplant due to end-stage lung disease secondary to non-CF bronchiectasis. The donor and recipient CMV serostatus is D+/R+. The patient’s initial peri-operative course was complicated by difficult explant, primary graft dysfunction, respiratory failure requiring prolonged mechanical ventilation, renal insufficiency and recurrent infectious concerns, including pseudomonas and stenotrophomonas pneumonias.